LOGIN  |  REGISTER
Recursion
Cue Biopharma

Relay Therapeutics to Host New Program and Platform Event on June 6, 2024

May 13, 2024 | Last Trade: US$4.83 0.21 4.55

CAMBRIDGE, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that the company will host a New Program and Platform event on Thursday, June 6, 2024 from 8:00 to 10:00 a.m. ET. During the event, the company will disclose new programs from its existing pre-clinical pipeline and review how the Dynamo™ platform led to these novel discoveries.

The event will be a hybrid format, with limited in-person attendance available to members of the investment community, and a simultaneous webcast will be available for all interested parties who wish to join virtually.

The live presentation can be accessed through Relay Therapeutics’ website under “Events” in the News & Events section through the following link: https://ir.relaytx.com/news-events/events-presentations. An archived replay of the webcast will be available for up to 30 days following the event. To participate in the live webcast, please register for the event here. It is recommended that participants register at least 15 minutes in advance of the event.

About Relay Therapeutics

Relay Therapeutics is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. As the first of a new breed of biotech created at the intersection of complementary techniques and technologies, Relay Therapeutics aims to push the boundaries of what’s possible in drug discovery. Its Dynamo™ platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. Relay Therapeutics’ initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. For more information, please visit www.relaytx.com or follow us on Twitter.

Contact:
Megan Goulart
617-545-5526
This email address is being protected from spambots. You need JavaScript enabled to view it.

Media:
Dan Budwick
1AB
973-271-6085
This email address is being protected from spambots. You need JavaScript enabled to view it.

Terns Pharmaceuticals

Stock Quote

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page